GLP-1受体激动剂对2型糖尿病患者短期与长期代谢控制的影响(3)
 |
| 第1页 |
参见附件。
[6] Yoder SM，Yang Q，Kindel TL，et al.Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats[J].Am J Physiol Gastrointest Lixer Physiol，2010，299(13)：476-485.
[7] Gautier JF，Fetita S，Sobngwi E，et al.Biological actions of the incretins GIP and GLP-1and therapeutic perspectives in patients with type 2diabetes[J].Diabetes Matab，2005，31(3pt1)：233.
[8] Gao Y，Yoon KH，Chuang LM，et al.Efficacy and safety of exenatide inpatients of Asian descent with type 2 diabetes inadequately controlled with metformin ormetformin and a sulphonylurea[J].Diabetes Res Clin Pract，2009，83(5)：69-76.
[9] 施广德，张晓兰，黄文龙.艾塞那肽对2型糖尿病患者的疗效观察[J].中国糖尿病杂志，2011(10)：770-772.
[10] 付鸿玉，刘冰梅，刘立波.艾塞那肽治疗2型糖尿病20例临床观察[J].中国医疗前沿,2011(18)：32，45.
[11] Buse JB，Rosenstock J，Sesti G，et al.Liralutide once a day versus exenatide twice a day for type 2 diabetes：a 26-week randomized，parallel-group，multinational，open-label trial(LEAD-6)[J].Lancet，2009，374(9683)：39-47.
[12] Erdogdu O，Nathanson D，Sjoholm A，et al.Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-，PKA-and P13K/Akt-dependent pathways and requires GLP-1 receptor[J].Mol Cell Endocrionl.2010，325(1/2)：26-35.
[13] Drucker DJ，Buse JB，Taylor K，et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes： a randomized，open-label，non-inferiority study[J].Lancet，2008 372(9645)：1240-250.
[14] 蔡玉立，文重远，黄兵.艾塞那肽治疗2型糖尿病对患者血脂影响的系统评价[J].医学研究杂志，2012，41(10)：116-120.
(收稿日期：2014-03-03)
您现在查看是摘要介绍页，详见PDF附件。